Repositioning Candidate Details
| Candidate ID: | R1567 |
| Source ID: | DB15598 |
| Source Type: | approved |
| Compound Type: | small molecule |
| Compound Name: | Ferric maltol |
| Synonyms: | Ferric maltol; Iron (III) maltol |
| Molecular Formula: | C18H15FeO9 |
| SMILES: | [Fe+3].CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1.CC1=C([O-])C(=O)C=CO1 |
| Structure: |
|
| DrugBank Description: | Ferric maltol is an iron(III) atom complexed with 3 maltol molecules to increase the bioavailability compared to iron(II), without depositing it in the duodenum as insoluble ferric hydroxide and phosphate. Ferric maltol has been described in literature since at least the late 1980s as a potential treatment for iron deficiency. Ferric maltol was granted FDA Approval on 25 July 2019. |
| CAS Number: | 33725-54-1 |
| Molecular Weight: | 431.154 |
| DrugBank Indication: | Ferric maltol is indicated to treat iron deficiency in adults. |
| DrugBank Pharmacology: | Ferric maltol is used to provide supplemental iron to patients with an iron deficiency. It has a wide therapeutic index as patients generally take 30mg twice daily, while concentrations of 20mg/kg may produce toxicity. Patients should be counselled regarding the risk of inflammatory bowel disease flares, iron overload, and accidental ingestion in children. |
| DrugBank MoA: | Ferric maltol dissociates as the iron atom is donated to unknown iron uptake mechanisms, possibly beta 3 integrin or divalent metal transporter 1, in the ileum and duodenum. Once the iron is in circulation, it then associates with transferrin and ferritin. |
| Targets: | Integrin beta-3 substrate; Natural resistance-associated macrophage protein 2 substrate |
| Inclusion Criteria: | Therapeutic strategy associated |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs | |
|---|---|---|---|---|---|
| S05 | Anti-inflammatory | inflammatory | Bile acid; TNF-a inhibitor; Dual PPAR-α and -δ agonists; Toll-Like Receptor; (TLR)-4 antagonist; Caspase inhibitor; ASK-1 inhibitor | Ursodeoxycholic Acid; Pentoxifylline; Elafibranor; JKB-121; Emricasan; Selonsertib; | Details |
| Diseases ID | DO ID | Disease Name | Definition | Class |
|---|